Polaryx Therapeutics
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
South Tower 140 E Ridgewood Ave Ste 415,...Phone Number
(201) 940-7236Website
www.polaryx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Polaryx Therapeutics
Polaryx Therapeutics is a late-stage clinical biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, which are rare inherited metabolic diseases. The company aims to address these conditions through innovative drug candidates that include new chemical entities and repurposed drugs, with a pipeline targeting diseases such as Krabbe, Sandhoff, and Niemann Pick types A and B. Polaryx is committed to creating formulations that ensure high compliance, particularly in pediatric populations, utilizing intranasal and oral delivery methods. Established in 2014, Polaryx Therapeutics operates under experienced leadership dedicated to the safe and effective commercialization of its therapies.Explore more
Polaryx Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Polaryx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Polaryx Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Polaryx Therapeutics is spiking on competitors!
Earning: See what the market has to say on Polaryx Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Polaryx Therapeutics has new funding data
Polaryx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Polaryx Therapeutics
Click to see if Polaryx Therapeutics had a recent Job posting/layoffs
Check if Polaryx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Polaryx Therapeutics
Find 2 more new buyers
Compare Similar Companies to Polaryx Therapeutics
Compare insights from companies similar to Polaryx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Polaryx Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Polaryx Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Polaryx Therapeutics.
Polaryx Therapeutics Tech Stack
A closer look at the technologies used by Polaryx Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Polaryx Therapeutics News & Media
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award WinnerPolaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia.Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Polaryx Therapeutics Receives U.S. FDA Fast Track DesignationsPolaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Polaryx Therapeutics
Sign Up For FreeTo access detailed company insights
Polaryx Therapeutics is a late-stage clinical biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, which are rare inherited metabolic diseases. The company aims to address these conditions through innovative drug candidates that include new chemical entities and rep... Read More
